Daiichi Sankyo Italia S.P.A. company information, Employees & Contact Information

AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study Seeking Alpha

Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-friendly culture Microsoft

Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. BioPharma Dive

Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd BioSpace

Japan's Daiichi Sankyo establishes third research institute in US BioSpectrum Asia

Daiichi Sankyo celebrates its roots and blooming future at DC cherry blossom festival Fierce Pharma

Daiichi Sankyo pays $132 million for Glycotope’s gatipotuzumab The Pharma Letter

IHH Healthcare arm increases damages sought from Daiichi Sankyo to ₹11,800 crore over Fortis stake dispute Mint

Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' Fierce Pharma

IHH seeks up to $1.7b in compensation from JP’s Daiichi Sankyo over Fortis deal Healthcare Asia Magazine

Daiichi Sankyo (TSE:4568): Exploring Valuation After Recent Share Price Uptick Yahoo Finance

Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO Pharmaceutical Technology

Enabling data-driven business with global digital transformation platform DXC Technology

Daiichi invests 1 bln eur near Munich to make precision cancer drugs Reuters

How Daiichi Sankyo Europe drives growth with digital and analytics McKinsey & Company

Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo Pharmaceutical Technology

Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal Fierce Pharma

MSD signs Daiichi Sankyo in multibillion dollar deal to develop ADCs Pharmaceutical Technology

Daiichi blasts 'malicious and defamatory' marketing complaints but still gets hit with serious violation Fierce Pharma

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Pharmaceutical Technology

IHH’s unit seeks up to $1.7 bil in compensation from Japan’s Daiichi Sankyo over Fortis deal The Edge Singapore

Daiichi Sankyo: Good Diversification Tool For U.S. Investors Seeking Alpha

Daiichi Sankyo to absorb manufacturing units in move to leverage ADC strength Fierce Pharma

Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang BioSpace

Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany Fierce Pharma

Daiichi Sankyo ups revenue forecast thanks to massive Merck deal Fierce Biotech

Daiichi Sankyo builds $152M ADC plant in China as Enhertu wins national coverage Fierce Pharma

Daiichi Sankyo tipped to dominate antibody-drug conjugate market through 2029 Fierce Pharma

Daiichi Sankyo Again Raises Enhertu Sales Forecast Driven by Non-US Growth BioSpace

Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case Fierce Pharma

Japanese health care firm Daiichi Sankyo acquires sports nutrition brand DNS NutraIngredients.com

Daiichi Sankyo, with tighter focus on oncology, sells 8 aging US cardiovascular drugs to diversifying Cosette Fierce Pharma

Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site BioSpace

Without Pfizer appeal, Daiichi Sankyo closes long-running ADC patent arbitration with $47M win Fierce Pharma

Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia Fierce Pharma

High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower (DSKYF) Seeking Alpha

AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data BioSpace

Daiichi Sankyo is Embarking on Mission Possible BioSpace

Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement Fierce Pharma

Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules Fierce Pharma

Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 Business Wire

AstraZeneca and Daiichi Sankyo’s Enhertu receives EU approval PharmaTimes

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe PMLiVE

AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer Seeking Alpha

Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs Business Wire

AstraZeneca, Daiichi's Enhertu steps into the FDA's fast lane for new stomach cancer use Fierce Pharma

Daiichi Sankyo poaches Kite's research lead Takeshita from parent Gilead Fierce Biotech

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu PMLiVE

Daiichi Sankyo taps CRO Syneos Health to help run ADC cancer drug work, including Enhertu Fierce Biotech

US agency nixes Seagen patent, handing Daiichi Sankyo a win in long-running Enhertu entanglement Fierce Pharma

After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period BioSpace

Daiichi Sankyo inks $200M licensing deal with Ultragenyx to boost gene therapy manufacturing Fierce Pharma

Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia PMLiVE

Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny Fierce Pharma

AstraZeneca and Daiichi Sankyo Ink $6 Billion Cancer Pact BioSpace

"No Clear Response" Ends Early-Stage Daiichi Sankyo ADC Program BioSpace

AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug Fierce Biotech

AstraZeneca And Daiichi Sankyo’s Zauberkugel (Magic Bullet) Seeking Alpha

Daiichi Sankyo rises most in five months on cancer drug approval The Japan Times

Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC Fierce Biotech

Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug Fierce Biotech

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar Reuters

Daiichi Sankyo eyes newer cancer drugs to stave off rivals The Japan Times

Japan's Daiichi Sankyo to make cutting-edge cancer treatments in China Nikkei Asia

Bayer’s Martin Hesse moves to Daiichi Sankyo Europe PMLiVE

IHH Healthcare unit files $179.5m lawsuit against Daiichi Sankyo over Fortis deal The Straits Times

Daiichi Sankyo's disastrous India foray with hybrid model Business Today